IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.
Document Type
Article
Publication Date
9-15-2018
JAX Source
Cancer Res 2018 Sep 15; 78(18):5243-5258
Volume
78
Issue
18
First Page
5243
Last Page
5258
ISSN
1538-7445
PMID
30012670
DOI
https://doi.org/10.1158/0008-5472.CAN-18-0413
Grant
CA034196, The Jackson Laboratory
Abstract
Inflammation affects tumor immune surveillance and resistance to therapy. Here, we show that production of IL1β in primary breast cancer tumors is linked with advanced disease and originates from tumor-infiltrating CD11c+ myeloid cells. IL1β production is triggered by cancer cell membrane-derived TGFβ. Neutralizing TGFβ or IL1 receptor prevents breast cancer progression in humanized mouse model. Patients with metastatic HER2- breast cancer display a transcriptional signature of inflammation in the blood leukocytes, which is attenuated after IL1 blockade. When present in primary breast cancer tumors, this signature discriminates patients with poor clinical outcomes in two independent public datasets (TCGA and METABRIC).Significance: IL1β orchestrates tumor-promoting inflammation in breast cancer and can be targeted in patients using an IL1 receptor antagonist. Cancer Res; 78(18); 5243-58.
Recommended Citation
Wu T,
Xu K,
Martinek J,
Young R,
Banchereau R,
George J,
Turner J,
Kim K,
Zurawski S,
Wang X,
Blankenship D,
Brookes H,
Marches F,
Obermoser G,
Lavecchio E,
Levin M,
Bae S,
Chung C,
Smith J,
Cepika A,
Oxley K,
Snipes G,
Banchereau J,
Pascual V,
O'Shaughnessy J,
Palucka A.
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer. Cancer Res 2018 Sep 15; 78(18):5243-5258